- Home
- CINT vs DAWN Comparison
CINT vs DAWN Comparison
Compare CINT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- DAWN
- Stock Information
- Founded
- CINT 1995
- DAWN 2018
- Country
- CINT Brazil
- DAWN United States
- Employees
- CINT N/A
- DAWN N/A
- Industry
- CINT EDP Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- DAWN Health Care
- Exchange
- CINT Nasdaq
- DAWN Nasdaq
- Market Cap
- CINT 803.4M
- DAWN 658.9M
- IPO Year
- CINT 2021
- DAWN 2021
- Fundamental
- Price
- CINT $5.57
- DAWN $6.38
- Analyst Decision
- CINT Buy
- DAWN Strong Buy
- Analyst Count
- CINT 7
- DAWN 6
- Target Price
- CINT $7.61
- DAWN $30.17
- AVG Volume (30 Days)
- CINT 87.5K
- DAWN 1.4M
- Earning Date
- CINT 08-15-2025
- DAWN 07-29-2025
- Dividend Yield
- CINT N/A
- DAWN N/A
- EPS Growth
- CINT 53.80
- DAWN N/A
- EPS
- CINT 0.24
- DAWN N/A
- Revenue
- CINT $444,135,000.00
- DAWN $161,922,000.00
- Revenue This Year
- CINT $521.47
- DAWN $17.98
- Revenue Next Year
- CINT $13.05
- DAWN $49.50
- P/E Ratio
- CINT $22.96
- DAWN N/A
- Revenue Growth
- CINT 3.04
- DAWN N/A
- 52 Week Low
- CINT $4.42
- DAWN $6.08
- 52 Week High
- CINT $8.04
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- CINT 43.06
- DAWN 44.72
- Support Level
- CINT $5.89
- DAWN $6.48
- Resistance Level
- CINT $5.94
- DAWN $7.00
- Average True Range (ATR)
- CINT 0.17
- DAWN 0.28
- MACD
- CINT -0.03
- DAWN -0.02
- Stochastic Oscillator
- CINT 23.33
- DAWN 14.77
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.